Advertisement

Bone Health in Women with Chronic Kidney Disease

  • Maryanne Sourial
  • Maria CocoEmail author
Chapter
First Online:

Abstract

Bone health maintenance is a major focus in the care of women. Women are especially vulnerable to bone disease. Women with CKD are even at greater risk for bone disease. This chapter discusses the evaluation of bone health in women with CKD as well as appropriate treatment options for these women.

Keywords

Chronic kidney disease in women Bone health with chronic kidney disease Women and chronic kidney disease Bone health in women Osteoporosis in women with chronic kidney disease Kidney disease and bone health in women 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Cosman F, de Beur SJ, MS LB, Lewiecki EM, Tanner R, Randall S, Lindsay R. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–81.CrossRefGoogle Scholar
  2. 2.
    Hung L, Hwang Y, Huang G, Liang C, Lin J. The influence of renal dialysis and hip fracture sites on the 10-year mortality of elderly hip fracture patients. Medicine. 2017;96(37):e7618.CrossRefGoogle Scholar
  3. 3.
    Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2012;23:525–32.Google Scholar
  4. 4.
    Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end stage renal disease. Kidney Int. 2000;58:396–9.CrossRefGoogle Scholar
  5. 5.
    Mittalhenkle A, Gillen DL, Stehman-breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44(4):672–9.CrossRefGoogle Scholar
  6. 6.
    Fishbane S, Hazzan AD, Jhaveri KD, Lin M, Lacson E. Bone parameters and risk of hip and femur fractures in patients on hemodialysis. Clin J Am Soc Nephrol. 2016;11:1063–72.CrossRefGoogle Scholar
  7. 7.
    Pimental A, Urena-Torres P, Zillikens MC, Bover J, Cohen-Solal M. Fractures in patients with CKD: a review by members of the European Calcified Tissue Society and European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017;92:1343–55.CrossRefGoogle Scholar
  8. 8.
    Boyce BF, Yao Z, Xing L. Osteoclasts have multiple roles in addition to bone resportion. Crit Rev Eukaryot Gene Expr. 2009;19(3):171–80.CrossRefGoogle Scholar
  9. 9.
    Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2009;2:56–64.CrossRefGoogle Scholar
  10. 10.
    Moorthi RN, Moe SM. Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int. 2013;84:886–94.CrossRefGoogle Scholar
  11. 11.
    Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res. 2010;89:331–4.CrossRefGoogle Scholar
  12. 12.
    Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys. 2010;503(1):118–28.CrossRefGoogle Scholar
  13. 13.
    Schoenau E, Rauch F. Biochemical markers of bone metabolism. In: Glorieux FH, Pettifor J, Jueppner H, editors. Pediatric bone. San Diego: Academic; 2003. p. 339–57.CrossRefGoogle Scholar
  14. 14.
    Cauley J. Estrogen and bone health in men and women. Steroids. 2015;99A:11–5.CrossRefGoogle Scholar
  15. 15.
    Naylor KL, McArthur E, Leslie W, Fraser L, Jamal SA, Cadarette SM, Pouget JG, Lok CE, Hodsman AB, Adachi JD, Garg AX. The three year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86:810.CrossRefGoogle Scholar
  16. 16.
    Nicholas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74:721–31.CrossRefGoogle Scholar
  17. 17.
    Malluche HH, Monier-Faugere CM, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2009;6(1):32–40.CrossRefGoogle Scholar
  18. 18.
    Moscowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988;123:2571–7.CrossRefGoogle Scholar
  19. 19.
    Tang L, et al. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int. 2002;26:75–84.CrossRefGoogle Scholar
  20. 20.
    Kirino S, et al. Regulation of bone metabolism in immunosuppressant [FK506]-treated rats. J Bone Miner Metab. 2004;22:554–60.CrossRefGoogle Scholar
  21. 21.
    Kubal C, Cockwell P, Gunson B, Jesky M, Hanvesakul R, Dronavalli V, Bonser RS, Neil D. Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring. Transplantation. 2012;93(4):407–11.CrossRefGoogle Scholar
  22. 22.
    Coco M, Pullman J, Cohen H, Lee S, Shapiro C, Solorzano C, Greenstein S, Glicklich D. Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol. 2012;23:1426–37.CrossRefGoogle Scholar
  23. 23.
    Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669–76.CrossRefGoogle Scholar
  24. 24.
    Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325:544–50.CrossRefGoogle Scholar
  25. 25.
    Evenepoel P, Behets GJ, Viaene L, D’Haese PC. Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int. 2016;91(2):469–76.CrossRefGoogle Scholar
  26. 26.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefGoogle Scholar
  27. 27.
    KDIGO 2017. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder [CKD-MBD]. Kidney Int. 2017;7:1–60s.CrossRefGoogle Scholar
  28. 28.
    Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92:743–53.CrossRefGoogle Scholar
  29. 29.
    Jamal SA, West SL, Nickolas TL. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int. 2014;15(1):71–6.CrossRefGoogle Scholar
  30. 30.
    Urena P, Hruby M, Ferreira A, Ang KS, deVernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–12.PubMedGoogle Scholar
  31. 31.
    Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254–62.CrossRefGoogle Scholar
  32. 32.
    Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–16.CrossRefGoogle Scholar
  33. 33.
    Quaseem A, Forcica MA, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39.CrossRefGoogle Scholar
  34. 34.
    Wilson LM, Rebhotz CM, Jirru E, Liu MC, Zhang A, Gayleard J, Chu Y, Robinson KA. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systemic review and meta-analysis. Ann Intern Med. 2017;166(9):649–58.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Albert Einstein College of Medicine, Montefiore Medical Center, Department of MedicineRenal DivisionBronxUSA

Personalised recommendations

Cite chapter

Buy options